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Introduction
Swiss incidence as well as mortality rates for liver cancer 
have increased only slightly over the last 20 years [1]. The 
ratio of the two is close to unity, indicating that cure from 
liver cancer is rare.
Malignant liver cancers represent primarily hepatocellu-
lar carcinomas (90%) followed by cholangiocarcinomas 
(10%). Other forms of malignant liver cancer, such as 
angiosarcoma, are extremely rare. Hepatocellular carci-
nomas and intrahepatic cholangiocarcinomas deserve our 
attention for several reasons. Firstly, their incidence is ris-
ing, and in some countries distinctly, as has been docu-
mented by a number of epidemiological studies in the last 
20 years [2, 3, 4]. Rising chronic hepatitis C infections 
and the surge in obesity and diabetes mellitus have been 
proposed as explanations for the increase in hepatocellular 
carcinoma [5, 6, 7, 8]. A second reason is the decidedly 
poor prognosis of hepatocellular carcinoma and cholangio-
carcinoma [9]. These tumours can grow extensively before 
the appearance of symptoms. When symptoms ultimately 
lead to diagnosis, the therapeutic options are limited and 
mainly palliative. Thirdly, both tumour types are often 
associated with underlying liver diseases [5, 3]. Eighty 
percent of the patients with hepatocellular carcinoma 
have a cirrhosis and cholangiocarcinoma is associated with 
cholestatic liver diseases, particularly primary scleros-
ing cholangitis. Reduced hepatic functions further limit 
treatment options. 
Thus, treatment of primary liver cancer is challenging 
and there is a large need for progress in the short-term 
and long-term outcomes in these patients. In the present 
manuscript, epidemiological information from tumour 
registries of several Swiss cantons has been combined to 
examine the survival pattern of patients diagnosed with 
primary liver cancer during the last 30 years.
Methods
This study is based on the National Core Dataset (NCD) 
managed by the National Institute for Cancer Epidemi-
ology and Registration (NICER) for the purpose of na-
tional cancer monitoring in Switzerland. Sixteen of 26 
Swiss cantons currently transmit cancer data annually to 
the NCD. Cancer cases from thirteen cantons were pooled 
for this report: Basel-Stadt and Basel-Landschaft (BS/BL), 
Fribourg (FR), Geneva (GE), Graubünden and Glarus 
(GR/GL), Lucerne (LU), St. Gallen, Appenzell Ausserrho-
den and Appenzell Innerrhoden (SG/AR/AI), Ticino (TI), 
Valais (VS) and Zurich (ZH). The cantons of Neuchâtel, 
Jura and Vaud could not be included, because they do not 
provide information on survival to the NCD.
Cancer registries recorded all incident cancer cases di-
agnosed in their resident population and assessed cases’ 
survival by active and/or passive follow-up. Cases were 
followed-up to 31 December 2010. We extracted 7,490 
malignant cancer diagnoses for liver and intrahepatic bile 
ducts (ICD-10 C22.0-C22.9) from 1980 to 2010. For 
the cantons BS and BL the latest available year of diag-
nosis was 2008. We excluded all cases diagnosed at death 
(N=850; 11.3%) or with a death certificate as the only 
source of information (N=285; 3.8%). Patients with mul-
tiple primary tumours were included [10]. Excluded were 
N=96 or 1.3% of cases, because no active follow-up has 
been performed. A total of 6,256 cases remained for anal-
ysis, with 90% of observations uncensored (i.e. patients 
who have died). Recent active follow-up was lacking for 
Table 1: Number of malignant hepatic cancer cases used for 
survival analysis in the Swiss national dataset, stratified by 
Swiss cantons.
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N=151 (2.4%) cases. The vital status of these cases was set 
lost to follow-up using the date of last contact. Because we 
did not assume survival up to 31 December 2010 in the 
absence of reported death, our survival estimates will be 
conservative.
Completeness of case ascertainment for hepatic cancer 
could be assessed in the cantons GE, GR/GL, SG/AR/AI, 
TI and VS and was found to be slightly higher than the 
international standard of at least 90% within 1.5 years 
after the date of diagnosis for diagnosis years 2005-2010 
[11]. Case finding via death certificates was substantial: 
between 7% and 38%, depending on cancer registry and 
diagnosis year. Two registries did not utilize death cer-
tificates for case finding during all diagnosis years: ZH 
(1980-1996) and BS/BL (1981-2001, 2008). If ZH and 
BS/BL were removed from the pooled dataset for the years 
indicated, the maximal deviation in survival proportion 
found in any of the analysis endpoints was 3.0% (for age-
group 55-64 during period 1990-1999).
Observed survival (OS) and relative survival (RS) were de-
rived for consecutive time intervals of increasing length 
after diagnosis during which the hazards were assumed 
to remain constant.Time intervals were: 0-0.1, 0.1- 0.3, 
0.3-0.6, 0.6-1.0, 1.0-1.5, 1.5-2.0, 2.0-2.5, 2.5-3.0, 3-4, 
4-5 and 5-6 years. RS was calculated as the ratio of the 
observed survival of cancer cases and the expected survival 
of persons in the general population matching in age, sex, 
calendar year of death and cantonal pool [12]. Expected 
cancer survival was estimated using the Ederer II meth-
od applied to all-cause mortality tables for the cantons 
combined [13]. All-cause death probabilities, transformed 
from age-, sex- and calendar year-specific death rates, were 
interpolated and smoothed using the Elandt-Johnson for-
mula [14]. RS ratios were estimated using the strs com-
mand (version 1.3.7) [15] written for the Stata Statisti-
cal Software [16]. Partially complete survival analysis was 
used for the comparison in Table 2. Period survival analy-
sis [17] was used for the analysis of time trends in Table 3. 
In brief, partially complete analysis describes the survival 
of cases defined by dates of diagnosis, and period analysis 
defines cases by follow-up dates. RS estimates were age-
standardized using weights specific for hepatic cancer from 
the International Cancer Survival Standards (ICSS) [18]. 
Standard weights for age groups were: 0.19 (0-54 years), 
0.23 (55-64), 0.29 (65-74) and 0.29 (75-99). Ninety-five 
Table 2: Observed and relative 
survival estimates after 
malignant hepatic cancer 
diagnosis, with 95% confidence 
intervals, by 10-year calendar 
period, age at diagnosis, years 
since diagnosis and sex. Data 
pooled from 12 Swiss cantons 
(ZH, SG/AR/AI, GE, BS/BL, TI, 
VS, GR/GL, and FR).
percent confidence intervals 
(95% CI) were estimated us-
ing Greenwood’s method [19] 
in partially complete analysis 
and in period analysis by ap-
plying the delta method to a 
transformation of the cumu-
lative hazard. For age-stan-
dardized RS, 95% CI were 
estimated as described in [18].
To test for linear time trends 
of RS, the annual percentage 
change (APC) was estimated 
with the Joinpoint Regression 
Program v4.0.4 [20].
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Results
The survival experiences of more than 6,200 persons diag-
nosed with malignant cancer of the liver or the intrahepat-
ic bile ducts contributed to this study (Tab. 1). The data 
pool contains increasing numbers of cancer registries over 
time. Until 1995, the cantons ZH, SG/AR/AI, GE and 
BS/BL contributed to the pool, whereas canton TI joined 
in 1996, canton FR in 2006 and canton LU in 2010. The 
cantons ZH and GE alone contributed almost 50% of the 
total cases. 
Men were about three times more often affected compared 
to Women. The median age at diagnosis was 68 years (in-
terquartile range IQR 60-75) for Men and 72 years (IQR 
63-79) for Women. Just five percent of patients were 
diagnosed below age 47. The age distribution of the pa-
tients remained stable over time. The most common pri-
mary malignancy was hepatocellular carcinoma, ranging 
from 50% - 90% depending on cancer registry. Validity 
of this estimate was limited by considerable differences in 
the frequency of unspecified neoplasms (ranging from 1% 
up to 40%, depending on cancer registry).
The survival experience of Men and Women was remark-
ably similar, for every age-group and diagnosis period 
analysed. This is shown in Tab. 2 for survival proportions 
at one and three years after diagnosis, and by the surviv-
al curves in Fig. 1. Estimations for survival proportions 
five years after diagnosis are not shown in Tab. 2 because 
they could not be reliably estimated in Women due to the 
smaller number of cases.
Men and Women shared equally in the prolongation of 
survival duration over calendar time. The age-standard-
ized relative survival (RS) proportions in Men, diagnosed 
between 1990 and 1999, were 27.9% and 11.8% for 
one and three years after diagnosis, respectively, and in 
Women, diagnosed in the same period, RS was 29.8% and 
11.6%, respectively. A decade later (2000-2009), the RS 
had improved considerably to 40.2% and 19.9% in Men 
and 42.3% and 19.4% in Women. 
Figure 1: Age- and sex-specific relative survival curves for two 
calendar periods of diagnosis (1990-1999 and 2000-2009). 
95% confidence intervals are shown for survival proportions 
at one and three years after diagnosis. Hepatic cancer cases 
were pooled from 12 Swiss cantons (ZH, SG/AR/AI, GE, BS/
BL, TI, VS, GR/GL, and FR).
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Temporal survival trends were analysed at higher resolution 
using seven consecutive time periods of three year duration, 
starting in 1990 and ending in 2010 (Tab. 3). Men and 
Women were analysed together and the age groups reduced 
to two. The enlarged number of observations per stratum al-
lowed estimation of five-year survival proportions. The an-
nual percentage changes (APC) were significantly larger than 
zero for short term RS (one year after diagnosis) as well as 
for long term survival (five years after diagnosis) and ranged 
from 3.9% to almost 10%. Persons above 75 years of age 
at diagnosis seemed to have gained equally or even slightly 
more than younger persons (APC 9.7% vs 5.9% for RS after 
five years, difference not significant). The APC in age-stan-
dardized RS proportions were 3.9% [CI 2.3-5.6%] and 5.6% 
[CI 2.7-8.7%] for one and five year survival, respectively. The 
overall shape of the trend was not linear but seemed to have 
been steepest during the time period 1997-2003. 
Discussion
Our results confirm that the prognosis of primary liver 
cancer is still poor. This emphasizes the role of primary 
prevention. It is important to treat patients with liver dis-
eases before they develop a cirrhosis, which places them at 
higher carcinogenic risk. Well-tolerated, efficacious treat-
ments against chronic hepatitis B and chronic hepatitis C 
infections are now available and they have been shown to 
decrease the rate of hepatocellular carcinoma [21, 22]. Re-
garding secondary prevention, relevant diagnostic proce-
dures such as ultrasonography, computed tomography and 
magnetic resonance imaging, have been introduced dur-
ing the last 20 years to detect hepatocellular carcinoma 
at an earlier stage. Since the Swiss trend in mortality did 
not decline relative to the incidence rate, it suggests that 
earlier diagnosis of liver cancer might have contributed to 
the observed prolongation of survival, measured as time 
from diagnosis to death or end of follow-up. Additional 
efforts could be made through active surveillance of pa-
tients at risk and thus offering curative treatments to a 
larger number of patients as has recently been shown for 
the Bern HCC cohort [23].
The observed improvements in survival of patients in Swit-
zerland could have several explanations, which are mutually 
non-exclusive. Novel and effective treatments of hepatocel-
lular carcinoma have been progressively introduced during 
the last 20 years. Selection of treatments has been facili-
tated with the introduction of the ‘BCLC’ algorithm [24] 
and in particular, the recognition in the late nineties, that 
patients with a limited tumour burden can be transplanted 
with a small risk of recurrence [25]. The application of the 
so-called «Milan criteria» not only cured patients with he-
patocellular carcinoma, but also stimulated physicians to 
Table 3: Trends in relative survival of hepatic cancer cases 
pooled from 13 Swiss cantons (ZH, SG/AR/AI, GE, BS/BL, 
TI, VS, GR/GL, FR, and LU) for successive three-year calendar 
periods of follow-up.
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find tumours at an earlier stage, which lead to better screen-
ing and clearer radiological definition of the diagnosis [26]. 
Furthermore, the use of other therapeutic options has 
been improved, such as transarterial chemoembolization 
(TACE), either as palliative intervention or as neoadjuvant 
treatment, the introduction of drug-eluting beads [27], and 
of a systemic targeted therapy against hepatocellular carci-
noma [28]. The contribution of such palliative treatments 
on long-term survival is limited in comparison with cura-
tive approaches such as transplantation [29] or innovative 
therapeutic combinations [30]. 
The main strength of our study is the large number of 
primary hepatic cancer cases that could be combined from 
thirteen Swiss cantons. The data spans 30 calendar years, 
thus allowing the analysis of changes over time. There are, 
however, important limitations to our study. Neither the 
histological type of the primary tumour nor the progres-
sion stage of the disease have been taken into account. It is 
likely to be hepatocellular carcinoma at a progressed stage 
in the majority of cases, but we cannot exclude distortion 
of our results by other forms of hepatic carcinoma or by 
changes in the case mix over time.
In conclusion, primary liver cancer should attract more 
attention in the medical community than it does at pres-
ent. The number of patients could be reduced by vaccina-
tion against hepatitis B and by treatment of chronic viral 
hepatitis, alcoholic liver disease and non-alcoholic ste-
atohepatitis. In addition, increased efforts such as active 
surveillance of patients at risk could be made in order to 
diagnose hepatic cancer at an earlier stage. 
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Ausgezeichnete Noten für 
die Forschungsförderung 
Rolf Marti, Stéphanie Buvelot Frei  
und Kurt Bodenmüller, Krebsliga Schweiz
Die Stiftung Krebsforschung Schweiz und die 
Krebsliga Schweiz leisten hervorragende Arbeit bei 
der Förderung der Krebsforschung in der Schweiz. Sie 
unterstützen Forschungsprojekte von ausgezeichneter 
Qualität, aus denen viele bedeutende Publikationen 
hervorgehen – mit Topwerten im internationalen 
Vergleich. Dies sind die Ergebnisse einer unabhängigen, 
extern durchgeführten Evaluation.
D’excellentes notes pour la promotion  
de la recherche 
La fondation Recherche suisse contre le cancer et la 
Ligue suisse contre le cancer réalisent un travail re-
marquable en matière de promotion de la recherche 
oncologique en Suisse. Elles soutiennent des projets 
d’excellente qualité qui génèrent un grand nombre de 
publications importantes et qui sont extrêmement bien 
notées en comparaison internationale. Tels sont les ré-
sultats d’une évaluation externe indépendante.
Pour en savoir plus: www.liguecancer.ch/pr-evaluation
Dank ihren zahlreichen Spenderinnen und Spendern ha-
ben die Stiftung Krebsforschung Schweiz (KFS) und die 
Krebsliga Schweiz (KLS) im Jahr 2013 die onkologische 
Forschung mit über 17 Millionen Franken unterstützt. 
Gefördert wurden insgesamt 63 Forschungsprojekte aus 
dem gesamten Spektrum der Krebsforschung, zehn Sti-
pendiaten, sieben Schweizer Forschungsorganisationen 
sowie 42 wissenschaftliche Kongresse, Workshops und 
weitere Projekte und Organisationen. 80% der Mittel 
stammten von der KFS und 20% steuerte die KLS bei. 
Zusätzlich dazu fördern diverse kantonale und regionale 
Krebsligen die Krebsforschung mit über drei Millionen 
Franken pro Jahr.
Umfassende unabhängige Evaluation
Hauptkriterium für den Entscheid, welche Projekte fi-
nanziert werden, ist die Qualität der eingereichten Arbei-
ten. Ein wichtiger Fokus liegt in der Unterstützung der 
patientennahen Forschung. Die Mitglieder der Wissen-
schaftlichen Kommission (WiKo) evaluieren zusammen 
mit weiteren internationalen Fachpersonen sämtliche Ge-
suche nach klar definierten wissenschaftlichen Kriterien. 
Zuständig für den Entscheid, welche Gesuche finanzielle 
Unterstützung erhalten, sind der Stiftungsrat der KFS 
und der Vorstand der KLS. Der Bereich Forschungsför-
derung der KLS («Scientific Office») fungiert als Kom-
petenzzentrum und operationelle Drehscheibe der For-
schungsförderung beider Organisationen.
Im Auftrag der Vorstände von KFS und KLS hat die Firma 
evalueSCIENCE Qualität und Effizienz der Forschungs-
förderung, die beteiligten Organe sowie Steuerung, Pro-
zesse und Strukturen überprüft. Die Auswertung basiert 
auf dem Zeitraum 1998–2012 sowie internationalen Stan-
dards (Methode: «Informed Peer Review» gemäss «Zu-
rich Model», eine an der Universität Zürich entwickelte 
Evaluationsmethode). Ausgangspunkt bildete ein umfang-
reicher, vom Bereich Forschungsförderung erarbeiteter 
Selbstbericht. Die Evaluation von evalueSCIENCE bein-
haltete drei Schwerpunkte: eine bibliometrische Analyse 
der wissenschaftlichen Publikationen, eine Online-Um-
frage bei den Forschenden und die Beurteilung durch eine 
unabhängige internationale Expertengruppe.
Bibliometrie: exzellenter «Output» 
Wie gut die Qualität einer Forschungsarbeit ist bzw. 
welche Bedeutung diese innerhalb eines bestimmten 
Forschungsgebiets hat, wird hauptsächlich durch zwei 
Faktoren bestimmt: in welcher Fachzeitschrift die Arbeit 
publiziert wurde («impact factor») und wie oft die Ar-
beit in weiteren Publikationen zitiert wurde («citations»). 
Je renommierter die Fachzeitschrift ist und je öfter die 
Publikation zitiert wird, desto bedeutender ist sie. Insge-
samt wurden über 400 von KFS bzw. KLS im Zeitraum 
1998–2006 finanzierte Forschungsprojekte quantitativ 
und qualitativ ausgewertet. 
Die wichtigsten Ergebnisse:
–  KFS und KLS förderten Forschungsarbeiten von ausge-
zeichneter Qualität. Insbesondere Projekte in den Be-
reichen Grundlagenforschung, epidemiologische und 
labororientierte klinische Forschung resultierten in Pu-
blikationen von grosser bis sehr grosser wissenschaftlicher 
Bedeutung im jeweiligen Forschungsgebiet. Auch die 
Fördereffizienz, d.h. der finanzielle Aufwand pro Publika-
tion, war für diese drei Forschungsbereiche am höchsten. 
–  Kleiner fiel im Vergleich der wissenschaftliche «Out-
put» sowie die Fördereffizienz bei patientenorientierten 
Forschungsprojekten aus. Zurückzuführen ist dies u.a. 
darauf, dass klinische Studien viel aufwendiger und 
teurer sind und es länger dauert, bis publizierbare Re-
sultate vorliegen. 
